Curium to Acquire Lantheus in Radiopharma Deal Worth Up to $8 Billion

Radiopharmaceutical company Curium has agreed to acquire Lantheus Holdings in a deal valued at up to $8 billion, a significant move that expands its presence in the high-growth market for radioactive-based diagnostics and cancer treatments.

Deal Structure and Terms

Under the agreement announced Monday, Lantheus shareholders are set to receive $102.50 per share in cash upon the deal's closing. The terms also include a contingent value right (CVR) that could provide an additional payment of up to $12 per share if certain sales milestones are achieved by 2030.

The total potential consideration of $114.50 per share represents a premium of approximately 14.9% to Lantheus's last closing price of $99.64. Curium, which is backed by private equity firm CapVest Partners, plans to finance the acquisition through a combination of debt and equity. The transaction is expected to be finalized in the first half of 2027.

Market Reaction and Analysis

Following the announcement, shares of Lantheus Holdings (LNTH) rose more than 2% in morning trading. However, some analysts noted the upfront cash offer was not as high as some investors may have anticipated. B. Riley Securities analyst Yuan Zhi described the $102.50 upfront payment as "a fair price but not a generous one," according to Reuters.

The merger could also attract close examination from regulators. Jones Trading analyst Justin Walsh told Reuters the deal may face "relatively high regulatory scrutiny" because both companies are significant players in the diagnostic radiopharmaceuticals market. The agreement follows a May report from Bloomberg News that Lantheus was considering a sale after receiving an offer from Curium.

Ad

A Hot Sector for M&A

The acquisition is the latest in a series of major deals within the radiopharmaceutical space, which uses radioactive compounds to diagnose and treat diseases like cancer. This sector has become a focal point for M&A activity in healthcare.

Recent notable transactions include:

• Bristol Myers Squibb buying RayzeBio for roughly $4.1 billion.
• AstraZeneca acquiring Fusion Pharmaceuticals in a deal worth up to $2.4 billion.
• Eli Lilly purchasing Point Biopharma for approximately $1.4 billion.

Lantheus is known for its diagnostic imaging agents, including its leading product Pylarify, which is used in PET scans to detect prostate cancer. Curium develops and supplies a broad range of radiopharmaceuticals for both diagnostic and therapeutic use.